Journal
ANNALS OF ONCOLOGY
Volume 27, Issue 3, Pages 546-547Publisher
OXFORD UNIV PRESS
DOI: 10.1093/annonc/mdv580
Keywords
-
Categories
Ask authors/readers for more resources
Nivolumab has shown promising early results in patients with advanced malignancies, including melanoma and lung cancer, with generally manageable side effects. On the other hand, recent studies showed that the immune activation caused by PD-1 blockade might promote severe autoimmune toxicity. Herein, we report a case of idiopathic thrombocytopenic purpura during nivolumab therapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available